Nov. 17, 2023—Vanderbilt researchers are working to better design immune therapies that attack tumors without also attacking healthy normal tissue in patients.
Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors
Aug. 8, 2023—A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
Aug. 3, 2023—Vanderbilt researchers found that T cells become “exhausted” within hours of encountering a tumor, challenging existing ideas about how T cells become dysfunctional.
Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.
Sep. 10, 2021—Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Aug. 5, 2021—A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
Feb. 27, 2020—Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.
Jan. 16, 2020—The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.